why choose us

First received: August 04, 2022

Clinical Trial: Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Study Status: Completed

Recruit Status: RECRUITING

Condition: TNBC - Triple-Negative Breast Cancer

Study Type: INTERVENTIONAL


Official Title: IIT2021-01-Shiao-CSF1Ri: Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

Brief Summary: This is an open-label prospective, single institution, Phase II study of pembrolizumab in combination with radiation therapy and CSF-1R inhibition in patients with high-risk TNBC.The primary objective is to assess the pathologic complete response (pCR) rate where pCR is defined as the absence of invasive disease in the breast and lymph nodes at the time of standard of care (SOC) treatment.Secondary objectives include evaluating the change in tumor infiltrating lymphocytes (TILs), safety and tolerability of the…

Read more